Statera Biopharma, Inc. – NASDAQ:STAB
Statera Biopharma stock price today
Statera Biopharma stock price monthly change
Statera Biopharma stock price quarterly change
Statera Biopharma stock price yearly change
Statera Biopharma key metrics
Market Cap | 7.14K |
Enterprise value | 7.69M |
P/E | -0.01 |
EV/Sales | 2.55 |
EV/EBITDA | -0.08 |
Price/Sales | 0.26 |
Price/Book | -0.07 |
PEG ratio | N/A |
EPS | -2.61 |
Revenue | 3.68M |
EBITDA | 47.35M |
Income | -95.42M |
Revenue Q/Q | 183.47% |
Revenue Y/Y | 1459.13% |
Profit margin | -3249.13% |
Oper. margin | -3100.33% |
Gross margin | 63.66% |
EBIT margin | -3100.33% |
EBITDA margin | 1284.12% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeStatera Biopharma stock price history
Statera Biopharma stock forecast
Statera Biopharma financial statements
| Dec 2021 | 1.25M | -77.23M | -6176.58% |
|---|---|---|---|
| Mar 2022 | 997.83K | -8.90M | -892.29% |
| Jun 2022 | 768.82K | -4.12M | -536.46% |
| Sep 2022 | 670.47K | -5.15M | -769.5% |
| 2022-08-15 | -0.02824 | -0.08297 |
|---|
| Dec 2021 | 21169685 | 22.67M | 107.12% |
|---|---|---|---|
| Mar 2022 | 13509689 | 15.94M | 118.02% |
| Jun 2022 | 13542336 | 20.46M | 151.11% |
| Sep 2022 | 12749125 | 22.91M | 179.76% |
| Dec 2021 | -8.12M | -96.91K | 858.95K |
|---|---|---|---|
| Mar 2022 | -3.76M | -6.45K | -2.89M |
| Jun 2022 | -168.51K | 0 | 500.13K |
| Sep 2022 | -801.52K | 0 | 711.65K |
Statera Biopharma alternative data
| Aug 2023 | 46 |
|---|---|
| Sep 2023 | 46 |
| Oct 2023 | 46 |
| Nov 2023 | 46 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 46 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
Statera Biopharma other data
| Period | Buy | Sel |
|---|---|---|
| Feb 2015 | 1891 | 0 |
| Quarter | Transcript |
|---|---|
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
-
What's the price of Statera Biopharma stock today?
One share of Statera Biopharma stock can currently be purchased for approximately $0.03.
-
When is Statera Biopharma's next earnings date?
Unfortunately, Statera Biopharma's (STAB) next earnings date is currently unknown.
-
Does Statera Biopharma pay dividends?
No, Statera Biopharma does not pay dividends.
-
How much money does Statera Biopharma make?
Statera Biopharma has a market capitalization of 7.14K. Statera Biopharma made a loss 174.41M US dollars in net income (profit) last year or -$0.08 on an earnings per share basis.
-
What is Statera Biopharma's stock symbol?
Statera Biopharma, Inc. is traded on the NASDAQ under the ticker symbol "STAB".
-
What is Statera Biopharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Statera Biopharma?
Shares of Statera Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Statera Biopharma's key executives?
Statera Biopharma's management team includes the following people:
- Mr. Michael Kevin Handley Chief Executive Officer, Pres & Chairman(age: 54, pay: $416,350)
- Dr. Clifford A. Selsky M.D., Ph.D. Chief Medical Officer(age: 76, pay: $197,920)
-
How many employees does Statera Biopharma have?
As Jul 2024, Statera Biopharma employs 46 workers.
-
When Statera Biopharma went public?
Statera Biopharma, Inc. is publicly traded company for more then 4 years since IPO on 28 Jul 2021.
-
What is Statera Biopharma's official website?
The official website for Statera Biopharma is staterabiopharma.com.
-
Where are Statera Biopharma's headquarters?
Statera Biopharma is headquartered at 2537 Research Boulevard, Fort Collins, CO.
-
How can i contact Statera Biopharma?
Statera Biopharma's mailing address is 2537 Research Boulevard, Fort Collins, CO and company can be reached via phone at +888 6138802.
Statera Biopharma company profile:
Statera Biopharma, Inc.
staterabiopharma.comNASDAQ
46
Biotechnology
Healthcare
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
Fort Collins, CO 80526
CIK: 0001318641
ISIN: US8575611046
CUSIP: 857561104
